These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25818403)

  • 1. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
    Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
    Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
    Steffensen KD; Adimi P; Jakobsen A
    Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
    Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
    Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
    Thaker PH; Brady WE; Lankes HA; Odunsi K; Bradley WH; Moore KN; Muller CY; Anwer K; Schilder RJ; Alvarez RD; Fracasso PM
    Gynecol Oncol; 2017 Nov; 147(2):283-290. PubMed ID: 28802766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
    Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
    Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
    Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
    Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
    Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer - an ancillary data analysis of the VELIA trial.
    Aghajanian C; Swisher EM; Okamoto A; Steffensen KD; Bookman MA; Fleming GF; Friedlander M; Moore KN; Tewari KS; O'Malley DM; Chan JK; Ratajczak C; Hashiba H; Wu M; Dinh MH; Coleman RL
    Gynecol Oncol; 2022 Feb; 164(2):278-287. PubMed ID: 34930617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
    Bell-McGuinn KM; Konner JA; Tew WP; Hensley ML; Iasonos A; Charpentier E; Mironov S; Sabbatini P; Aghajanian C
    Int J Gynecol Cancer; 2016 Feb; 26(2):255-60. PubMed ID: 26745694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
    Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
    Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
    Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.
    Reiss KA; Herman JM; Armstrong D; Zahurak M; Fyles A; Brade A; Milosevic M; Dawson LA; Scardina A; Fischer P; Hacker-Prietz A; Kinders RJ; Wang L; Chen A; Temkin S; Horiba N; Stayner LA; Siu LL; Azad NS
    Gynecol Oncol; 2017 Mar; 144(3):486-490. PubMed ID: 28109627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Martin LP; Sill M; Shahin MS; Powell M; DiSilvestro P; Landrum LM; Gaillard SL; Goodheart MJ; Hoffman J; Schilder RJ
    Gynecol Oncol; 2014 Mar; 132(3):526-30. PubMed ID: 24361733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.